DFO、DFO*与DFOcyclo*用于89Zr免疫PET的体内外稳定性直接比较
该研究在体外血浆、PBS及EDTA或DFO竞争条件下,并在HER2+ SKOV-3与HER2- MDA-MB-231荷瘤小鼠中,比较[89Zr]Zr-DFOcyclo*、[89Zr]Zr-DFO*与[89Zr]Zr-DFO标记曲妥珠单抗的稳定性。结果显示DFOcyclo*与DFO*在EDTA竞争下稳定性高于DFO,DFOcyclo*-曲妥珠单抗在过量DFO竞争下显著更稳定,且注射后168小时骨摄取显著低于DFO。作者认为DFOcyclo*是有望成为89Zr免疫PET新标准螯合剂的候选。
要点
- DFOcyclo*-曲妥珠单抗在过量DFO竞争下体外稳定性显著高于DFO与DFO*偶联物(p < 0.001)。
- 注射后168小时,DFOcyclo*与DFO*组股骨和膝关节骨摄取均显著低于DFO组(p < 0.001)。
- 三组偶联物细胞结合与内化相似,血液、肿瘤及其他器官摄取在168小时无显著差异。
核心结论
- 89Zr标记的DFOcyclo*及其曲妥珠单抗偶联物体外和体内稳定性高于目前常用的89Zr-DFO-曲妥珠单抗。
- DFOcyclo*是有望成为89Zr免疫PET新临床标准螯合剂的候选。
研究设计与样本
- 研究在体外比较DFO、DFO*与DFOcyclo*单独及偶联曲妥珠单抗后在人间血浆、PBS及过量EDTA或DFO中的稳定性。
- 使用HER2表达SKOV-3细胞评估免疫反应分数、IC50与内化率。
- 在皮下HER2+ SKOV-3或HER2- MDA-MB-231荷瘤小鼠中,于注射后7天行PET/CT成像与离体组织定量分析。
主要发现
- 89Zr标记的DFO、DFO*与DFOcyclo*在人间血浆中稳定长达7天。
- 与EDTA竞争时,DFO*与DFOcyclo*稳定性高于DFO;与过量DFO竞争时,DFOcyclo*-曲妥珠单抗显著比DFO和DFO*偶联物更稳定(p < 0.001)。
- 三种偶联物的细胞结合与内化相似。
- HER2+ SKOV-3荷瘤小鼠注射后168小时,DFOcyclo*-曲妥珠单抗组股骨1.5 ± 0.3%ID/g、膝关节2.1 ± 0.4%ID/g,DFO*-曲妥珠单抗组股骨2.0 ± 0.3%ID/g、膝关节2.68 ± 0.4%ID/g,均显著低于DFO-曲妥珠单抗组股骨4.5 ± 0.6%ID/g、膝关节7.8 ± 0.6%ID/g(p < 0.001)。
- 注射后168小时,血液水平、肿瘤摄取及其他器官摄取在三组间无显著差异;HER2- MDA-MB-231荷瘤小鼠中DFOcyclo*与DFO组肿瘤摄取分别为16.2 ± 10.1%ID/g与19.6 ± 3.2%ID/g,显著低于HER2+ SKOV-3荷瘤小鼠的72.1 ± 14.6%ID/g与93.1 ± 20.9%ID/g(p < 0.001),而骨摄取相似。
关键数值与推荐
- 体外稳定性评估条件包括人间血浆、PBS、过量EDTA或DFO竞争。
- 体内比较指标为注射后168小时PET/CT与离体组织分析中的骨摄取、血液水平、肿瘤摄取及其他器官摄取。
临床怎么用
- 对于89Zr免疫PET,DFOcyclo*可降低体内89Zr释放所致的骨摄取,同时保持肿瘤摄取与血液水平。
- DFOcyclo*作为候选螯合剂,可能改善89Zr免疫PET的体内稳定性与图像定量准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Currently, the most commonly used chelator for labelling antibodies with 89Zr for immunoPET is desferrioxamine B (DFO). However, preclinical studies have shown that the limited in vivo stability of the 89Zr-DFO complex results in release of 89Zr, which accumulates in mineral bone. Here we report a novel chelator DFOcyclo*, a preorganized extended DFO derivative that enables octacoordination of the 89Zr radiometal. The aim was to compare the in vitro and in vivo stability of [89Zr]Zr-DFOcyclo*, [89Zr]Zr-DFO* and [89Zr]Zr-DFO. METHODS: The stability of 89Zr-labelled chelators alone and after conjugation to trastuzumab was evaluated in human plasma and PBS, and in the presence of excess EDTA or DFO. The immunoreactive fraction, IC50, and internalization rate of the conjugates were evaluated using HER2-expressing SKOV-3 cells. The in vivo distribution was investigated in mice with subcutaneous HER2+ SKOV-3 or HER2- MDA-MB-231 xenografts by PET/CT imaging and quantitative ex vivo tissue analyses 7 days after injection. RESULTS: 89Zr-labelled DFO, DFO* and DFOcyclo* were stable in human plasma for up to 7 days. In competition with EDTA, DFO* and DFOcyclo* showed higher stability than DFO. In competition with excess DFO, DFOcyclo*-trastuzumab was significantly more stable than the corresponding DFO and DFO* conjugates (p < 0.001). Cell binding and internalization were similar for the three conjugates. In in vivo studies, HER2+ SKOV-3 tumour-bearing mice showed significantly lower bone uptake (p < 0.001) 168 h after injection with [89Zr]Zr-DFOcyclo*-trastuzumab (femur 1.5 ± 0.3%ID/g, knee 2.1 ± 0.4%ID/g) or [89Zr]Zr-DFO*-trastuzumab (femur 2.0 ± 0.3%ID/g, knee 2.68 ± 0.4%ID/g) than after injection with [89Zr]Zr-DFO-trastuzumab (femur 4.5 ± 0.6%ID/g, knee 7.8 ± 0.6%ID/g). Blood levels, tumour uptake and uptake in other organs were not significantly different at 168 h after injection. HER2- MDA-MB-231 tumour-bearing mice showed significantly lower tumour uptake (p < 0.001) after injection with [89Zr]Zr-DFOcyclo*-trastuzumab (16.2 ± 10.1%ID/g) and [89Zr]Zr-DFO-trastuzumab (19.6 ± 3.2%ID/g) than HER2+ SKOV-3 tumour-bearing mice (72.1 ± 14.6%ID/g and 93.1 ± 20.9%ID/g, respectively), while bone uptake was similar. CONCLUSION: 89Zr-labelled DFOcyclo* and DFOcyclo*-trastuzumab showed higher in vitro and in vivo stability than the current commonly used 89Zr-DFO-trastuzumab. DFOcyclo* is a promising candidate to become the new clinically used standard chelator for 89Zr immunoPET.
引用
- Raavé R, Sandker G, Adumeau P, et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET. Eur J Nucl Med Mol Imaging. 2019. PMID: 31161258. doi:10.1007/s00259-019-04343-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。